Cancer Family
Sarcoma
CI-CAN-00000344SARExplore in graph →
635 active trials17 approved drugs182 evidence items
- NCIt
- C9118
- OncoTree
- SARCNOS
- DOID
- 1115
- MeSH
- D012509
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000344SARExplore in graph →
Clinical trials
2,688 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (367)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06721689 | PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors(PEEL-224) | recruiting | Phase 1 / Phase 2 | 59 | Theodore LaetschOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07038278 | 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma(5-ALARMS) | not yet recruiting | Early Phase 1 | 20 | University of Colorado, DenverOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT02389244 | A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas(REGOBONE) | completed | Phase 2 | 163 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03006848 | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | completed | Phase 2 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03400826 | Effects of Simvastatin on Uterine Leiomyoma Size | active not recruiting | Phase 2 | 60 | Johns Hopkins UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04022213 | A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum | active not recruiting | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05026736 | Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07211737 | NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03069378 | A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | active not recruiting | Phase 2 | 41 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04299113 | Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma | active not recruiting | Phase 1 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04624178 | A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma | active not recruiting | Phase 2 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06660810 | Neoadjuvant Intralesional Injection of Talimogene Laherparepvec | active not recruiting | Phase 2 | 2 | John RiethOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 67 | University of California, IrvineOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03261544 | Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method? | recruiting | — | 50 | Duke UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT07377747 | Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma(ReLaPSe) | recruiting | — | 100 | Australia and New Zealand Sarcoma AssociationOTHER | 8 | Jul 15, 2026 | clinicaltrials |
| NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | not yet recruiting | Early Phase 1 | 80 | Indiana UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07602777 | A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) | recruiting | Phase 1 / Phase 2 | 113 | GlaxoSmithKlineINDUSTRY | 3 | Jul 15, 2026 | clinicaltrials |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT06580002 | Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | recruiting | Phase 2 | 75 | University of California, IrvineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07352761 | Bilateral Uterine Artery Occlusion During Laparoscopic Myomectomy | completed | N/A | 60 | Alexandria UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07575724 | Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma | not yet recruiting | Phase 2 | 3,300 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06796543 | Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma(TARGET-RT) | recruiting | N/A | 70 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 4 | Jul 10, 2026 | clinicaltrials |
| NCT07696169 | Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers | not yet recruiting | — | 1,000 | Shenzhen Third People's HospitalOTHER | 0 | Jul 10, 2026 | clinicaltrials |
| NCT07321912 | Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma | recruiting | Phase 2 | 406 | Milton S. Hershey Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT02650986 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | active not recruiting | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04946357 | Neoadjuvant Irradiation of Extremity Soft Tissue Sarcoma With Ions(EXTREM ION) | active not recruiting | N/A | 42 | University Hospital HeidelbergOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06103669 | Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)(VALOROUS) | recruiting | N/A | 250 | University of California, DavisOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03960177 | Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma | completed | Early Phase 1 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05109494 | Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas | suspended | Phase 2 | 30 | University of Wisconsin, MadisonOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06327477 | Proton-Spatially Fractionated Radiotherapy and Standard Radiation Therapy for the Treatment of Newly Diagnosed Retroperitoneal Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 28 | Northwestern UniversityOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03635632 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | active not recruiting | Phase 1 | 94 | Baylor College of MedicineOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04037527 | Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities | terminated | Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06710756 | Lead-212 PSV359 Therapy for Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 112 | Perspective TherapeuticsINDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 25 | Kaiser PermanenteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07684287 | A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma | not yet recruiting | Phase 2 | 40 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07685405 | Identification of Circulating Biomarkers Associated With Extracellular Vesicles in Sarcomas(BIOVES) | recruiting | — | 16 | Istituto Ortopedico RizzoliOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03874455 | Tazemetostat Expanded Access Program for Adults With Solid Tumors | no longer available | — | — | Epizyme, Inc.INDUSTRY | 0 | Jul 2, 2026 | clinicaltrials |
| NCT03972930 | Hypofractionated Radiotherapy for Soft Tissue Sarcomas | active not recruiting | Phase 2 | 48 | University of Wisconsin, MadisonOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04225429 | Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma | no longer available | — | — | Epizyme, Inc.INDUSTRY | 0 | Jul 2, 2026 | clinicaltrials |
| NCT04925089 | Localized Leiomyosarcoma Biomarker Protocol | recruiting | — | 40 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06981637 | Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)(MELODY) | recruiting | Phase 2 | 81 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06414434 | BTX-A51 in Patients With Liposarcoma or CIC-rearranged Sarcoma | active not recruiting | Phase 1 | 24 | Michael Wagner, MDOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07134192 | Fluorescence-Guided Optimization of Sarcoma Margins(FOCUS) | recruiting | N/A | 90 | University of AarhusOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04751383 | Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma | terminated | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 2 | Jun 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 22, 2026source: clinicaltrials